According to Zen Score, the 3 best pharma stocks to buy right now are:
1. Neurocrine Biosciences (NASDAQ:NBIX)
Neurocrine Biosciences (NASDAQ:NBIX) is the top pharmaceutical stock with a Zen Score of 64, which is 39 points higher than the pharmaceutical industry average of 25. It passed 21 out of 33 due diligence checks and has strong fundamentals. Neurocrine Biosciences has seen its stock return 41.31% over the past year, overperforming other pharmaceutical stocks by 48 percentage points.
Neurocrine Biosciences has an average 1 year
price target of $158.00, an upside of 15.58% from Neurocrine Biosciences's current stock price of $136.70.
Neurocrine Biosciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Neurocrine Biosciences, 60% have issued a Strong Buy rating, 20% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Pacira Biosciences (NASDAQ:PCRX)
Pacira Biosciences (NASDAQ:PCRX) is the second best pharmaceutical stock with a Zen Score of 64, which is 39 points higher than the pharmaceutical industry average of 25. It passed 20 out of 33 due diligence checks and has strong fundamentals. Pacira Biosciences has seen its stock lose -31.41% over the past year, underperforming other pharmaceutical stocks by -25 percentage points.
Pacira Biosciences has an average 1 year
price target of $46.71, an upside of 58.78% from Pacira Biosciences's current stock price of $29.42.
Pacira Biosciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Pacira Biosciences, 28.57% have issued a Strong Buy rating, 71.43% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Lantheus Holdings (NASDAQ:LNTH)
Lantheus Holdings (NASDAQ:LNTH) is the third best pharmaceutical stock with a Zen Score of 62, which is 37 points higher than the pharmaceutical industry average of 25. It passed 20 out of 33 due diligence checks and has strong fundamentals. Lantheus Holdings has seen its stock lose -23.18% over the past year, underperforming other pharmaceutical stocks by -17 percentage points.
Lantheus Holdings has an average 1 year
price target of $99.17, an upside of 30.45% from Lantheus Holdings's current stock price of $76.02.
Lantheus Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Lantheus Holdings, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.